Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3932MR)

This product GTTS-WQ3932MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ3932MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8518MR IVTScrip™ mRNA-Anti-B4GALNT1, Hu3F8(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu3F8
GTTS-WQ13210MR IVTScrip™ mRNA-Anti-PCSK9, PF-04950615(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-04950615
GTTS-WQ13403MR IVTScrip™ mRNA-Anti-ERBB2, PRO132365(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PRO132365
GTTS-WQ4538MR IVTScrip™ mRNA-Anti-PDCD1, BMS-936558(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-936558
GTTS-WQ183MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ6698MR IVTScrip™ mRNA-Anti-SLC34A2, DNIB0600A(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA DNIB0600A
GTTS-WQ8566MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ15334MR IVTScrip™ mRNA-Anti-TNF, TNFRSF1B-Fc(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA TNFRSF1B-Fc
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW